Na+/K+ ATPase Inhibitors
1 drugsAbout Na+/K+ ATPase
The Na+/K+ ATPase, or sodium-potassium pump, is an enzyme in the plasma membrane of animal cells. It actively transports sodium ions out and potassium ions into the cell using ATP, establishing electrochemical gradients for nerve impulse transmission and muscle contraction.
The Na+/K+ ATPase is a drug target in the cardiovascular area, as evidenced by the approved drug CARDIOGEN-82. Currently, there is no genetic evidence data available linking variations in the Na+/K+ ATPase gene to specific diseases.
Na+/K+ ATPase is targeted by one FDA-approved drug, CARDIOGEN-82, a small molecule. This drug, developed by BRACCO, was first approved in 1989 for cardiovascular indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Cesarean Section Complications with only 1 trials.
Top Na+/K+ ATPase Drugs
BRACCO is the only company with an approved drug targeting Na+/K+ ATPase.
The lack of competition suggests a high barrier to entry or an underexplored market.
Na+/K+ ATPase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Na+/K+ ATPase, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Na+/K+ ATPase Clinical Trials 1 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Na+/K+ ATPase Drug Approval Timeline (1989 - 1989)
The only approved drug, CARDIOGEN-82, was approved in 1989.
The lack of recent approvals indicates a potential for innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: Moderate (7 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 9 clinical trials targeting Na+/K+ ATPase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities